Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Functional evaluation of dendritic cells and extracellular vesicles as immunotherapy for breast cancer

Abstract

Dendritic cells (DCs) play critical roles in recognizing and presenting antigens to T cells. They secrete dendritic cell-derived extracellular vesicles (DC-sEVs), which could mimic the function of DCs. Therefore, we explore the possibility of using DC-sEVs as a potential personalized vaccine in this study. We compared the efficacy of DCs and DC-sEVs on stimulating the immune system to target breast cancer cells and found that DC-sEVs had significantly more MHC molecules on the surface when compared to the parental DCs. In our in vivo and in vitro testing, Dc-sEVs showed significant advantages over DCs, regarding efficacy, safety, storage, and potential delivery advantages. DC-sEVs were able to suppress the growth of immune-cold breast tumors, while DCs failed to do so. These results indicate the strong potential utility of DC-sEVs as a personalized immunotherapy for breast cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: MHC I and MHC II are retained and enriched on the surface of DC-sEVs.
Fig. 2: In vitro comparison of antigen-presentation abilities between DC-sEVs and DCs.
Fig. 3: Comparison of biodistribution and adverse effects between DC-sEVs and DCs in vivo.
Fig. 4: Comparison of anti-tumor effect between DC-sEVs and DCs in vivo.
Fig. 5: Comparison of anti-tumor effect between DC-sEVs and DCs in immune-cold 4T1 tumor.

Similar content being viewed by others

Data availability

All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials.

References

  1. Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20:7–24.

    Article  PubMed  CAS  Google Scholar 

  2. Mpakali A, Stratikos E. The role of antigen processing and presentation in cancer and the efficacy of immune checkpoint inhibitor immunotherapy. Cancers (Basel). 2021;1:134.

    Article  Google Scholar 

  3. Bandola-Simon J, Roche PA. Dysfunction of antigen processing and presentation by dendritic cells in cancer. Mol Immunol. 2019;113:31–7.

    Article  PubMed  CAS  Google Scholar 

  4. Chen X, Shao Q, Hao S, Zhao Z, Wang Y, Guo X, et al. CTLA-4 positive breast cancer cells suppress dendritic cells maturation and function. Oncotarget. 2017;8:13703–15.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Gervais A, Leveque J, Bouet-Toussaint F, Burtin F, Lesimple T, Sulpice L, et al. Dendritic cells are defective in breast cancer patients: a potential role for polyamine in this immunodeficiency. Breast Cancer Res. 2005;7:R326–35.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Cintolo JA, Datta J, Mathew SJ, Czerniecki BJ. Dendritic cell-based vaccines: barriers and opportunities. Future Oncol. 2012;8:1273–99.

    Article  PubMed  CAS  Google Scholar 

  7. Mastelic-Gavillet B, Balint K, Boudousquie C, Gannon PO, Kandalaft LE. Personalized dendritic cell vaccines-recent breakthroughs and encouraging clinical results. Front Immunol (Review). 2019;10:766.

    Article  Google Scholar 

  8. Tanyi JL, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R, et al. Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci Transl Med. 2018;10:eaao5931.

    Article  PubMed  Google Scholar 

  9. Qian D, Li J, Huang M, Cui Q, Liu X, Sun K. Dendritic cell vaccines in breast cancer: Immune modulation and immunotherapy. Biomed Pharmacother. 2023;162:114685.

    Article  PubMed  CAS  Google Scholar 

  10. Abdi K, Singh NJ, Matzinger P. Lipopolysaccharide-activated dendritic cells: “exhausted” or alert and waiting? J Immunol. 2012;188:5981–9.

    Article  PubMed  CAS  Google Scholar 

  11. Yamanaka R, Homma J, Yajima N, Tsuchiya N, Sano M, Kobayashi T, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res. 2005;11:4160–7.

    Article  PubMed  CAS  Google Scholar 

  12. van de Loosdrecht AA, van Wetering S, Santegoets SJAM, Singh SK, Eeltink CM, den Hartog Y, et al. A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia. Cancer Immunol Immunother. 2018;67:1505–18.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Thery C, Regnault A, Garin J, Wolfers J, Zitvogel L, Ricciardi-Castagnoli P, et al. Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. J Cell Biol. 1999;147:599–610.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Wu K, Lyu F, Wu S-Y, Sharma S, Deshpande RP, Tyagi A, et al. Engineering an active immunotherapy for personalized cancer treatment and prevention of recurrence. Sci Adv. 2023;9:eade0625.

    Article  PubMed  CAS  Google Scholar 

  15. Huda MN, Nurunnabi M. Potential application of exosomes in vaccine development and delivery. Pharm Res. 2022;39:2635–71.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Lu Z, Zuo B, Jing R, Gao X, Rao Q, Liu Z, et al. Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models. J Hepatol. 2017;67:739–48.

    Article  PubMed  CAS  Google Scholar 

  17. Wahlund CJE, Gucluler G, Hiltbrunner S, Veerman RE, Naslund TI, Gabrielsson S. Exosomes from antigen-pulsed dendritic cells induce stronger antigen-specific immune responses than microvesicles in vivo. Sci Rep. 2017;7:17095.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Andre F, Chaput N, Schartz NE, Flament C, Aubert N, Bernard J, et al. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol. 2004;172:2126–36.

    Article  PubMed  CAS  Google Scholar 

  19. Admyre C, Johansson SM, Paulie S, Gabrielsson S. Direct exosome stimulation of peripheral humanT cells detected by ELISPOT. Eur J Immunol. 2006;36:1772–81.

    Article  PubMed  CAS  Google Scholar 

  20. Utsugi-Kobukai S, Fujimaki H, Hotta C, Nakazawa M, Minami M. MHC class I-mediated exogenous antigen presentation by exosomes secreted from immature and mature bone marrow derived dendritic cells. Immunol Lett. 2003;89:125–31.

    Article  PubMed  CAS  Google Scholar 

  21. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med. 1998;4:594–600.

    Article  PubMed  CAS  Google Scholar 

  22. Yang ZZ, Kim HJ, Villasboas JC, Chen YP, Price-Troska T, Jalali S, et al. Expression of LAG-3 defines exhaustion of intratumoral PD-1(+) T cells and correlates with poor outcome in follicular lymphoma. Oncotarget. 2017;8:61425–39.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Wu M, Zheng D, Zhang D, Yu P, Peng L, Chen F, et al. Converting immune cold into hot by biosynthetic functional vesicles to boost systematic antitumor immunity. iScience. 2020;23:101341.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. Segura E, Nicco C, Lombard B, Veron P, Raposo G, Batteux F, et al. ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming. Blood. 2005;106:216–23.

    Article  PubMed  CAS  Google Scholar 

  25. Deb A, Gupta S, Mazumder PB. Exosomes: a new horizon in modern medicine. Life Sci. 2021;264:118623.

    Article  PubMed  CAS  Google Scholar 

  26. Wang W, Li J, Wu K, Azhati B, Rexiati M. Culture and identification of mouse bone marrow-derived dendritic cells and their capability to induce T lymphocyte proliferation. Med Sci Monit. 2016;22:244–50.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. Madaan A, Verma R, Singh AT, Jain SK, Jaggi M. A stepwise procedure for isolation of murine bone marrow and generation of dendritic cells. J Biol Method. 2014;1:e1.

    Article  Google Scholar 

  28. Nair S, Archer GE, Tedder TF. Isolation and generation of human dendritic cells. Curr Protoc Immunol. 2012;Chapter 7:Unit7 32.

    Google Scholar 

  29. Chometon TQ, Siqueira MDS, Sant Anna JC, Almeida MR, Gandini M, Martins de Almeida Nogueira AC, et al. A protocol for rapid monocyte isolation and generation of singular human monocyte-derived dendritic cells. PLoS ONE. 2020;15:e0231132.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  30. Peterson T. Densitometric analysis using NIH image. North American Vascular Biology Organization (NAVBO) eNewsletter. 2010;16:3.

  31. Wu K, Feng J, Lyu F, Xing F, Sharma S, Liu Y, et al. Exosomal miR-19a and IBSP cooperate to induce osteolytic bone metastasis of estrogen receptor-positive breast cancer. Nat Commun. 2021;12:5196.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Wu K, Fukuda K, Xing F, Zhang Y, Sharma S, Liu Y, et al. COX2-MMP1 pathway promotes brain metastasis by tampering with blood-brain barrier and supporting tumor initiating cells in the brain microenvironment. Cancer Res. 2015;75:2250.

    Article  Google Scholar 

  33. Zhao D, Wu K, Sharma S, Xing F, Wu SY, Tyagi A, et al. Exosomal miR-1304-3p promotes breast cancer progression in African Americans by activating cancer-associated adipocytes. Nat Commun. 2022;13:7734.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Acknowledgements

We thank Dr. Ravi Nandan Singh, Ph.D. (Wake Forest University) for kindly providing the assistance in NTA of the sEVs. This work was supported by NIH grants RO1CA173499, R01CA185650, R01CA205067, and W81XWH2110075 from the Department of Defense (to K Watabe), and NIH T32CA247819 (to K Wu). This study used various Core Facilities and Departmental Shared Equipment resources including Cellular Imaging Shared Resources, Tumor Tissue and Pathology Shared Resource Cell and Viral Vector Core Laboratory and FC Shared Resources that are supported by the Comprehensive Cancer Center of Wake Forest University NCI, National Institutes of Health Grant (P30CA012197).

Author information

Authors and Affiliations

Authors

Contributions

Conception and design: FL, K Wu, K Watabe. Development of methodology: FL, K Wu, K Watabe. Acquisition of data (provided animals, acquired and managed patient specimens, provided facilities, etc.): FL, K Wu, SYW, RS, RPD, AT, IR, SY, K Watabe. Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): FL, K Wu, SYW, K Watabe. Writing, review, and/or revision of the manuscript: FL, K Wu, IR, SY, K Watabe. Administrative, technical, or material support: K Wu, RPD, K Watabe. Study supervision: K Watabe.

Corresponding author

Correspondence to Kounosuke Watabe.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lyu, F., Wu, K., Wu, SY. et al. Functional evaluation of dendritic cells and extracellular vesicles as immunotherapy for breast cancer. Oncogene 43, 319–327 (2024). https://doi.org/10.1038/s41388-023-02893-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41388-023-02893-2

Search

Quick links